Hofmann Amun G
FIFOS-Forum for Integrative Research & Systems Biology, 1170 Vienna, Austria.
J Clin Med. 2025 Sep 1;14(17):6184. doi: 10.3390/jcm14176184.
The role of vascular endothelial growth factor (VEGF) in intimal hyperplasia has been investigated and discussed numerous times in the literature, producing contrary results and controversial outcomes. In particular, research concerned with the effects of VEGF after catheter-mediated injuries regarding the development of neointimal hyperplasia resulted in diverging conclusions. A systematic review based on PRISMA principles using MEDLINE was conducted. In summary, 66 publications met the qualifying criteria to be included in this review. VEGF can both cause and attenuate neointimal hyperplasia depending on its site of application and production. Endogenous VEGF produced in the media and adventitia promotes intimal hyperplasia after vascular injury, while exogenous VEGF delivered through drug eluting-stents or by gene therapy can ameliorate re-endothelialization and thereby inhibit intima hyperplasia. The understanding of post-injury released cytokines such as VEGF holds great promise for currently used therapeutic applications and potential for applications to be investigated in the future.
血管内皮生长因子（VEGF）在内膜增生中的作用在文献中已被多次研究和讨论，结果相互矛盾且存在争议。特别是，关于导管介导损伤后VEGF对新生内膜增生发展的影响的研究得出了不同的结论。基于PRISMA原则，使用MEDLINE进行了系统综述。综上所述，66篇出版物符合纳入本综述的合格标准。VEGF根据其应用部位和产生方式，既能导致内膜增生，也能减轻内膜增生。中膜和外膜产生的内源性VEGF在血管损伤后促进内膜增生，而通过药物洗脱支架或基因治疗递送的外源性VEGF可改善再内皮化，从而抑制内膜增生。对损伤后释放的细胞因子如VEGF的理解，对于目前使用的治疗应用具有巨大的前景，也为未来有待研究的应用提供了潜力。
